Genprex
GNPX
8 hedge funds and large institutions have $426K invested in Genprex in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 14 closing their positions.
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
60% less funds holding
Funds holding: 20 → 8 (-12)
63% less capital invested
Capital invested by funds: $1.17M → $426K (-$739K)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$586K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$184K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$142K |
| 3 |
Renaissance Technologies
New York
|
-$83K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$44K |
| 5 |
State Street
Boston,
Massachusetts
|
-$39.7K |
GNPX Hedge Fund Activity: Q1 2024 in Review
8 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q1 2024, worth a combined $426K — down 63% from $1.17M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GNPX and 2 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $586K. The largest seller was Vanguard Group, cutting an estimated $184K.
- 8 institutional investors held Genprex (GNPX) as of Q1 2024, down from 20 in Q4 2023.
- Funds reported $426K of Genprex stock for Q1 2024, down 63% quarter-over-quarter.
- 2 funds opened new Genprex positions in Q1 2024 and 14 closed out, a net change of -12 holders.
- The largest Genprex buyer in Q1 2024 was Armistice Capital, an estimated $586K added.
- The largest Genprex seller in Q1 2024 was Vanguard Group, an estimated $184K sold.
Based on aggregated 13F filings for Q1 2024.